公开(公告)号：EP2197489B2

公开(公告)日：2020-04-01

申请号：EP08835652.2

申请日：2008-10-06

申请人： ZymoGenetics, Inc.

发明人： BRANDT, Cameron, S. ,  KENNEDY, Jacob, J. ,  XU, Wenfeng ,  YI, Eugene, C. ,  FOX, Brian, A. ,  GAO, Zeren ,  SIVAKUMAR, Pallavur, V.

IPC分类号： C07K16/28 ,  A61K47/68 ,  C07K14/705 ,  A61K39/395

公开(公告)号：EP2274008A2

公开(公告)日：2011-01-19

申请号：EP09724060.0

申请日：2009-03-27

申请人： ZymoGenetics, Inc.

发明人： SIVAKUMAR, Pallavur, V. ,  GILBERTSON, Debra, G. ,  SNAVELY, Marshall, D. ,  MABRY, George, R. ,  YI, Eugene, C. ,  YAO, Yue ,  PRESNELL, Scott, R.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFR² and neutralizes PDGFR² activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein: LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443; LCDR2 has the amino acid sequence shown in SEQ ID NO: 434; LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444; HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445; HCDR2 has the amino acid sequence shown in SEQ ID NO: 437; HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442

公开(公告)号：EP1750749A2

公开(公告)日：2007-02-14

申请号：EP05735743.6

申请日：2005-04-04

申请人： ZymoGenetics, Inc.

发明人： KLUCHER, Kevin, M. ,  KINDSVOGEL, Wayne, R. ,  SIVAKUMAR, Pallavur, V. ,  HENDERSON, Katherine, E.

IPC分类号： A61K38/20

CPC分类号： A61K38/20 ,  A61K38/21 ,  A61K38/212 ,  A61K38/57 ,  A61K47/60 ,  C07K14/54 ,  A61K2300/00

摘要： IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.

公开(公告)号：EP1793845A2

公开(公告)日：2007-06-13

申请号：EP05797809.0

申请日：2005-07-29

申请人： ZymoGenetics, Inc.

发明人： DOYLE, Sean ,  KLUCHER, Kevin, M. ,  SIVAKUMAR, Pallavur, V. ,  KINDSVOGEL, Wayne, R. ,  CHAN, Chung

IPC分类号： A61K38/20

CPC分类号： A61K38/20 ,  A61K38/21 ,  A61K47/60 ,  C07K14/54 ,  C07K14/715 ,  C07K14/7155 ,  A61K2300/00

摘要： Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.

公开(公告)号：EP1697418A2

公开(公告)日：2006-09-06

申请号：EP04811758.4

申请日：2004-11-19

申请人： ZymoGenetics, Inc.

发明人： XU, Wenfeng ,  KINDSVOGEL, Wayne, R. ,  CHEN, Zhi ,  HUGHES, Steven, D. ,  CHANDRASEKHER, Yasmin, A. ,  DILLON, Stacey, R. ,  LEHNER, Joyce, M. ,  SIADAK, Anthony, W. ,  SIVAKUMAR, Pallavur, V. ,  MOORE, Margaret, D.

IPC分类号： C07K16/24 ,  A61K38/20

CPC分类号： C07K16/2866 ,  A61K38/1793 ,  A61K38/20 ,  A61K47/60 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/244 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30

摘要： The present invention relates to blocking the activity of IL-20 receptor polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 receptor antibodies and binding partners, including anti-IL-20RA, anti-IL-20RB and anti-IL-20RA/IL-20RB antibodies as well as methods for antagonizing IL-20RA and IL-20RB, either individually or together, using such antibodies and binding partners.

摘要翻译： 本发明提供一种结合多肽做可以结合SEQ ID NO：2的多肽竞争：从所述组包括选择2或3与由杂交瘤表达的单克隆抗体：（a）所述的杂交瘤克隆262.4.1.2.2.1（ATCC [PTA-5350]）; （B）的杂交瘤克隆262.5.1.6.4.4（ATCC [PTA-5351]）; 和（c）杂交瘤克隆262.7.1.3.2.4（ATCC [PTA-5352]）。

公开(公告)号：EP1758610B1

公开(公告)日：2012-07-04

申请号：EP05756320.7

申请日：2005-05-20

申请人： ZymoGenetics, Inc.

发明人： KINDSVOGEL, Wayne, R. ,  HUGHES, Steven, D. ,  HOLLY, Richard, D. ,  CLEGG, Christopher, H. ,  FOSTER, Donald, C. ,  JOHNSON, Rebecca, A. ,  HEIPEL, Mark, D. ,  SIVAKUMAR, Pallavur, V.

IPC分类号： A61K39/395 ,  A61P35/00 ,  A61K38/20

CPC分类号： C07K16/32 ,  A61K38/20 ,  A61K39/395 ,  A61K39/39558 ,  C07K16/2818 ,  C07K16/2896 ,  C07K2317/732 ,  A61K2300/00

摘要： Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.

公开(公告)号：EP1963369A2

公开(公告)日：2008-09-03

申请号：EP06850198.0

申请日：2006-11-28

申请人： Zymogenetics, Inc.

发明人： SIVAKUMAR, Pallavur, V. ,  JASPERS, Stephen, R.

IPC分类号： C07K16/24 ,  A61K39/00 ,  C07K14/54

CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2319/30 ,  Y10S530/809

摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

摘要翻译： 鉴定结合IL-21蛋白的单克隆抗体。 这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。 描述了杂交瘤和产生抗IL-21单克隆抗体的方法。 单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征 综合征，多发性硬化症，类风湿性关节炎，憩室炎，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，牛皮癣关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤 ，干燥综合征，肾小球性肾炎，IgA肾病，移植物宿主病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

公开(公告)号：EP1812476A1

公开(公告)日：2007-08-01

申请号：EP05816060.7

申请日：2005-10-21

申请人： ZymoGenetics, Inc.

发明人： XU, Wenfeng ,  KINDSVOGEL, Wayne, R. ,  CHANDRASEKHER, Yasmin, A. ,  DILLON, Stacey, R. ,  LEHNER, Joyce, M. ,  SIADAK, Anthony, W. ,  SIVAKUMAR, Pallavur, V. ,  MOORE, Margaret, D.

IPC分类号： C07K16/28 ,  C07K14/715

CPC分类号： C07K16/244 ,  A61K49/0008 ,  A61K2039/505 ,  C07K16/2866 ,  C07K2319/30 ,  Y10S530/809

摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.

公开(公告)号：EP1692180A2

公开(公告)日：2006-08-23

申请号：EP04811735.2

申请日：2004-11-19

申请人： ZymoGenetics, Inc.

发明人： XU, Wenfeng ,  KINDSVOGEL, Wayne, R. ,  CHEN, Zhi ,  HUGHES, Steven, D. ,  CHANDRASEKHER, Yasmin, A. ,  DILLON, Stacey, R. ,  LEHNER, Joyce, M. ,  SIADAK, Anthony, W. ,  SIVAKUMAR, Pallavur, V. ,  MOORE, Margaret, D.

IPC分类号： C07K16/24 ,  A61K38/20

CPC分类号： C07K16/2866 ,  A61K38/1793 ,  A61K38/20 ,  A61K47/60 ,  A61K2039/505 ,  C07K14/54 ,  C07K14/7155 ,  C07K16/244 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30

摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.

公开(公告)号：EP2411407A1

公开(公告)日：2012-02-01

申请号：EP10722828.0

申请日：2010-03-26

申请人： Zymogenetics, Inc.

发明人： PAN, Qi ,  BIRKS, Carl, W. ,  SIVAKUMAR, Pallavur, V.

IPC分类号： C07K14/71 ,  C12N15/62 ,  C07K16/22 ,  A61K39/395

CPC分类号： C07K14/71 ,  A61K38/00 ,  C07K16/22 ,  C07K2317/73 ,  C07K2319/00 ,  C12N15/62

摘要： Disclosed are bispecific binding proteins comprising a antibody/soluble receptor bispecific binding protein that reduces the biological activity of both VEGF-A and FGF. The FGF binding moieties are generally soluble FGFR3 or FGFR2. An Fc polypeptide is fused to the C-terminus of the FGF binding moiety and VEGF-A binding moiety are polypeptides fused using peptide or polypeptide linker sequences, and can be expressed as single bispecific binding protein. The bispecific antibody/soluble receptor binding proteins can be used to treat cancers characterized by solid tumor growth as well as other diseases.